Analytical Performance Evaluation of Three Commercial Rapid Nucleic Acid Assays for SARS-CoV-2
Authors:
- Jie YiJYJie Yi
- Xiao HanXHXiao Han
- Ziyi WangZWZiyi Wang
- Yu ChenYCYu Chen
- Yingchun XuYXYingchun Xu
- Jie WuJWJie Wu
Open Access
- 1 August 2021
- journal article
- research article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 14, 3169-3174
Abstract
Purpose: To cope with the SARS-CoV-2 epidemic, several rapid nucleic acid assays have been approved for use, but the analytical performance has not been well evaluated. In this report, two key performance parameters, analytical sensitivity (limit of detection) and reproducibility, of three approved rapid nucleic acid assays were assessed using heat-inactivated SARS-CoV-2 culture supernatants quantified by digital PCR. Methods: The LOD (limit of detection) and reproducibility of three approved rapid nucleic acid assays using their own instruments were assessed, while the LOD and reproducibility of two assays on a 7500 Real-Time instrument were assessed at the same time. Results: Using their own instruments, 100% of samples with 1150 copies/mL viral RNA could be detected by the Da An and Coyote assays, while 90% of samples could be detected by the Ustar assay; yet, for 525 copies/mL and 287.5 copies/mL viral RNA, the detection rate of the Ustar assay was higher than that of either the Da An or Coyote assays. However, the three assays did not produce statistically significant results with the three different concentrations of viral RNA (P=0.46, 0.46 and 0.46). Using a 7500 Real-Time instrument, Da An and Coyote assays did not produce statistically significant results with the 1150, 525 and 287.5 copies/mL viral RNA (P> 0.99, > 0.99 and > 0.99). The positive and negative detection rates of the three assays in the intra- and inter-assay stages were 100% on both their own instruments and the 7500 real-time PCR instrument. Conclusion: Positive or strongly positive samples can be detected by the rapid nucleic acid assay, but the analytical performance should be optimized, and comprehensive evaluations are also required.Keywords
This publication has 20 references indexed in Scilit:
- Update on serologic testing in COVID–19Clinica Chimica Acta, 2020
- Sensitivity, Specificity and Predictive Values of Molecular and Serological Tests for COVID-19: A Longitudinal Study in Emergency RoomDiagnostics, 2020
- Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosisInternational Immunopharmacology, 2020
- Laboratory diagnosis of SARS-CoV-2 - A review of current methodsJournal of Infection and Public Health, 2020
- Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020Clinica Chimica Acta, 2020
- Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2Journal of Clinical Microbiology, 2020
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected PneumoniaNew England Journal of Medicine, 2020
- A Novel Coronavirus Emerging in China — Key Questions for Impact AssessmentNew England Journal of Medicine, 2020
- Laboratory diagnosis of emerging human coronavirus infections – the state of the artEmerging Microbes & Infections, 2020
- Molecular and point-of-care diagnostics for Ebola and new threats: National POCT policy and guidelines will stop epidemicsExpert Review of Molecular Diagnostics, 2018